Log in

Healthcare

Trial data, approvals, and what they are worth

Readouts, FDA decisions, drug pricing and payer behaviour, sized in revenue rather than in press-release adjectives.

What Big Funds Own42 fundsWhat Berkshire, Bridgewater and other big funds reported holding last quarter.What Analysts Expect16 stocksRatings and price targets from the big institutions, each with its public source.

2026-10-21

OpenAI Bought a $20 Million Startup: In Drug Development, Scheduling Is the Bottleneck, Not Science insight cover
Private Company
21 min read

OpenAI Bought a $20 Million Startup: In Drug Development, Scheduling Is the Bottleneck, Not Science

OpenAI's October 20, 2026 acquisition of Orchestra Bio did not buy a laboratory. It bought the software layer that coordinates discovery, preclinical, manufacturing and clinical work — the planning layer that decides which experiment runs, which batch ships and which trial starts. The strategic signal is that the contested layer in drug development is no longer the model but the operating system around it, and that OpenAI can now bundle the two. With roughly $25 billion of foundation capital behind it and a client list that includes Moderna, Novo Nordisk and Thermo Fisher, the winners are the companies that own scarce physical capacity and clean balance sheets — Medpace, Samsung Biologics, WuXi Biologics — while the exposed layer is point-solution discovery software that owns no workflow, no backlog and no capacity.

Orchestra Bio's disclosed funding: ~$20MAcquisition announced: Oct 20, 2026
Read article

2026-10-20

Beijing Banned Selling Biotech Platforms, Not Licensing Them — and Only 5 of 121 China Deals Were Ownership Transfers insight cover
Markets / Event
21 min read

Beijing Banned Selling Biotech Platforms, Not Licensing Them — and Only 5 of 121 China Deals Were Ownership Transfers

Beijing's October 16 draft catalogue adds five biomedical technologies to China's export-control list, but the prohibition bites only on transfers of intellectual property ownership: licensing, contract research and production services stay outside the regime. The restriction therefore lands on the 5-of-121 ownership-transfer slice of a market that did as much as $110 billion of licensing in the first half of 2026, not on the licensing itself. What reprices is who can own a platform, what Chinese service providers are worth, and how little structural room Western buyers have left in China-linked deals.

China biotech licensing, H1 2026: $110BDeals involving an ownership transfer: 5 of 121
Read article

2026-10-19

TriGemX's $160M PIPE Pits a TRPM8 Pill Against AbbVie's $742M Migraine Franchise — and the Phase 2b Miss Won't Go Away insight cover
IPO
TCGX · TGEM•15 min read

TriGemX's $160M PIPE Pits a TRPM8 Pill Against AbbVie's $742M Migraine Franchise — and the Phase 2b Miss Won't Go Away

TriGemX Bio (formerly Kallyope) is taking a Phase 3 TRPM8 migraine drug public through a SPAC merger with TCGX Acquisition Corp, locking in ~$246M of gross proceeds and a ~$600M pro-forma EV under the new TriGemX Bio ticker on Nasdaq. The thesis hinges on elismetrep clearing AbbVie's $742M Q2 2026 migraine franchise with a triptan-resistant mechanism no CGRP inhibitor has touched — but the Phase 2b primary endpoint already missed conventional significance at P=0.0650, and the $160M PIPE runs straight into a mid-2027 readout. The PIPE itself is the real signal: anchored by TCG Crossover Fund III (the SPAC sponsor's own affiliate), with The Column Group and Viking Global Investors repeating from the $94M crossover round — a quality of money that says this is a thesis bet, not a momentum trade.

Total gross proceeds: $246MPIPE financing: $160M
Read article

2026-10-16

Healthcare's Biggest Day of 2026: Inside the Oct 15 Trade That Rerated an Entire Sector insight cover
Markets / Event
14 min read

Healthcare's Biggest Day of 2026: Inside the Oct 15 Trade That Rerated an Entire Sector

October 15 delivered the cleanest sector rotation of the year — a 550-point Dow surge alongside a 2.5% rally in the S&P 500 Health Care Sector as a hot PPI print and CoreWeave's bond yield touching 15% forced capital out of AI-credit exposure and into healthcare, the only cyclically-defensive sector where valuation and earnings momentum line up. UnitedHealth's Q3 beat on Oct 13 set the table, the Sep +1.3% PPI print at 8:30 a.m. on the 15th cleared the path, and HCA's Q3 print on Oct 27 is the next binary catalyst. Healthcare trades at roughly 18x forward earnings versus the S&P 500's 21x; the next move belongs to whoever reads the credit signal first.

S&P 500 Health Care Sector: +2.5%Dow Jones Industrial Average: +1.08% / +550 pts
Read article

2026-10-15

J&J Slid 6% on a Beat — The Two-Speed Split Inside Its $25.4B Quarter insight cover
Earnings
JNJ · ABBV•9 min read

J&J Slid 6% on a Beat — The Two-Speed Split Inside Its $25.4B Quarter

Johnson & Johnson topped top- and bottom-line consensus in Q3 FY2026 — $25.4B sales (+5.9% reported) and $2.59 adjusted EPS — while lifting its FY26 guide to $11.05–$11.15. Shares still closed down ~6% because MedTech undershot the $8.71B consensus by ~$70M and a $5.5B talc charge crushed GAAP EPS to $0.09, exposing a two-speed franchise. The investor question is which competitors — AbbVie in immunology or Abbott, Medtronic, Boston Scientific, Stryker and Intuitive Surgical in devices — can attack J&J's barbell as Q4's VARIPULSE Pro approval and OTTAVA robotics launch land.

Reported sales: $25.4BAdjusted diluted EPS: $2.59
Read article

2026-10-14

Galderma Pays 4.5x Sales for ZO Skin — Physician-Dispensed Is Where the 2026 Consumer Multiple Has Moved insight cover
Industry News
GALD.SW · BX•12 min read

Galderma Pays 4.5x Sales for ZO Skin — Physician-Dispensed Is Where the 2026 Consumer Multiple Has Moved

Galderma agreed to buy ZO Skin Health from Blackstone and the Obagi family for a $1.5B enterprise value in cash — a ~4.5x sales multiple on ZO's roughly $330M trailing revenue, well above the 2.6–2.8x trading multiples of Estée Lauder and Unilever. The market took Galderma's shares down more than 7% on the news because the deal is slightly dilutive to 2027 EBITDA, but the premium it paid signals exactly which consumer sub-segment now anchors prestige skincare valuations: physician-dispensed, where L'Oréal's dermatology, Galderma's Alastin and ZO, and Amorepacific's AESTURA already command premium economics.

Deal value (enterprise): $1.5BZO Skin TTM revenue (to Jun 2026): ~$330M
Read article
Stargardt Patient #1 Just Got Science Corp's PRIMA — The BCI Vision Trade Now Has a Real FDA-Anchored Inherited-Blindness Catalyst insight cover
Industry News
BLTE · NPCE•13 min read

Stargardt Patient #1 Just Got Science Corp's PRIMA — The BCI Vision Trade Now Has a Real FDA-Anchored Inherited-Blindness Catalyst

Science Corporation's PRIMA retinal implant — already CE-marked for geographic atrophy AMD with NEJM-published 78% responder rates — was implanted in its first Stargardt disease patient at Sydney Eye Hospital in May 2026, publicly disclosed Oct. 13. That moves the vision-restoration BCI trade from lab demo to a defined regulatory clock, with a US FDA decision now expected in early 2027 sitting just days after Belite Bio's tinlarebant PDUFA on Feb. 12, 2027. Listed investors have multiple ways to play the inheritance-blindness race: device via the only public BCI in NeuroPace, drug via Belite Bio and Ocugen, and AMD-GA incumbents through Biogen and Alcon.

First Stargardt implant procedure: May 2026PRIMAvera 36-month responder rate: 78%
Read article

2026-10-13

Ultrahuman Tied a Smart Ring to a Government — And Oura Just Lost Its Pricing Power for 13 Days insight cover
Industry News
12 min read

Ultrahuman Tied a Smart Ring to a Government — And Oura Just Lost Its Pricing Power for 13 Days

Bengaluru-based Ultrahuman signed a two-year MoU with Abu Dhabi's public health agency to deploy a wearable-agnostic biological-age model across the UAE — landing ten days after Oura shelved its $15B Nasdaq listing. The timing reopens the smart-ring subscription question: with Oura's planned IPO off the table and a private challenger already locking up government distribution, the 89%-gross-margin membership tape is about to be repriced, not the 80%-hardware tape investors were underwriting.

Oura S-1 TTM revenue: $1.4BOura FY2025 revenue: $908M
Read article

2026-10-11

Humana Just Made Medicare Advantage the Live Tape — A 20%-to-95% 4-Star Flip While UNH and ELV Slide insight cover
Earnings
16 min read

Humana Just Made Medicare Advantage the Live Tape — A 20%-to-95% 4-Star Flip While UNH and ELV Slide

Humana's share of Medicare Advantage members in 4-star+ plans jumped from 20% in 2026 to 95% for 2027, unlocking an estimated $4.8B in 2028 CMS quality-bonus payments — even as UnitedHealth slid to 67% (from 81%) and Elevance slipped to 45% (from 53%). The Oct 9 ratings release re-priced HUM's tape: the stock closed up 11.6% at $431.87 with after-hours at $435.00, Baird lifted its price target to $596 from $390, and the BCBSA's Sep 23–24 AI-upcoding study now frames commercial peers — not HUM — as the exposed side of the cost equation.

HUM 4-star+ MA share: 20% → 95%HUM Oct 9 stock move: +$44.75 (+11.6%)
Read article

2026-10-10

Bambusa's IPO Puts a Dupixent-Plus-Nemluvio Bispecific on the 2026 Dermatology Tape insight cover
IPO
16 min read

Bambusa's IPO Puts a Dupixent-Plus-Nemluvio Bispecific on the 2026 Dermatology Tape

Bambusa Therapeutics filed on Oct. 9, 2026 for a ~$100M Nasdaq listing under BBTX to fund a Phase 2b atopic dermatitis trial of BBT001, the only clinical-stage bispecific combining IL-4Rα (Dupixent's target) and IL-31 (Nemluvio's target) — supported by a striking 78.95% placebo-adjusted EASI reduction at Week 6 in Phase 1b/2a. With just $71.5M of cash and a going-concern flag as of Sept. 30, the IPO is existential, not opportunistic, and it prices into the same seven-day window as TRexBio's $116.7M Phase 1b AD listing, Attovia's now-trading-down IL-31 program, and Veradermics' +645% aesthetic-derm surge. The event reframes the entire dermatology-IBEX cohort: clinical-stage AD assets with mechanism wedges are getting funded, while narrow cosmetic dermatology is repricing higher.

Bambusa IPO target (S-1 placeholder): $100MBBT001 Week 6 EASI reduction vs placebo: -78.95%
Read article

2026-10-08

argenx's Sjögren's Flop Erased ~$9B — And Just Rewrote the FcRn Class Math insight cover
Earnings
NVS · JNJ•9 min read

argenx's Sjögren's Flop Erased ~$9B — And Just Rewrote the FcRn Class Math

argenx halted its Phase 3 UNITY trial of subcutaneous efgartigimod in Sjögren's disease after an IDMC concluded the study could not meet its primary endpoint, knocking ~16% off the share price on October 8, 2026 and erasing roughly $9B in market value. With Novartis's ianalumab already winning NEPTUNUS for Sjögren's and J&J's Imaavy holding a wAIHA monopoly, the premium that has paid for argenx's ~11x P/S multiple looks narrower — and the FcRn expansion story now belongs to Roche-/Janssen-/Novartis-led readouts, not argenx. The remaining Vyvgart pillars (ALKIVIA myositis win, ITP data, Empasiprubart MMN pending) keep the franchise alive but do not replace what Sjögren's TAM would have added.

Trial halted: Phase 3 UNITYPrimary endpoint: clinESSDAI change
Read article
Healthleap's $38M AI Just Made Every Adult Inpatient a Daily Triage Decision — And UNH's 86.7% MCR, Epic's 43.7% EHR Grip, and the Nurse-Ratio Fight Are All Now on Notice insight cover
Industry News
14 min read

Healthleap's $38M AI Just Made Every Adult Inpatient a Daily Triage Decision — And UNH's 86.7% MCR, Epic's 43.7% EHR Grip, and the Nurse-Ratio Fight Are All Now on Notice

Healthleap closed a $38M round (Oct 7, 2026) on 50-hospital traction, with one Penn Medicine site alone producing $23.8M of annualized impact — 27% more severe-malnutrition diagnoses and 8,632 bed-days saved. The product writes daily nutrition-risk scores straight into the EHR flowsheet, sits upstream of CDI, and bills on a three-year, per-licensed-bed, outcome-based contract. For investors, the wedge is that frontline AI has stopped being a documentation tool: it now substitutes for the manual screening nurses used to do, funnels previously missed E43 claims into the $7,250-per-claim MCC bucket, and shortens the LOS that insurers like UnitedHealth, Elevance, and Humana pay for.

Total raised (Seed + Series A): $38MHospital customers: 50+
Read article

2026-10-06

McKesson Pays 11.9x EBITDA for Option Care — Half What Cencora Just Paid for OneOncology insight cover
Industry News
OPCH · COR•14 min read

McKesson Pays 11.9x EBITDA for Option Care — Half What Cencora Just Paid for OneOncology

McKesson is buying Option Care Health for $5.8B alongside CD&R, not to roll up oncology practices but to lock in the home-infusion channel that feeds them. The 11.9x EBITDA multiple looks like a bargain next to Cencora's 19x for OneOncology, but only because infusion economics — squeezed by PBMs and exposed to CVS's exit — sit a tier below practice-platform economics. The deal completes a $10.5B, 14-month McKesson oncology build-out spanning drug distribution, the US Oncology Network (3,300+ providers post-Florida Cancer Specialists), Precision Medicine Group, and now last-mile infusion delivery.

Option Care deal value: $5.8BOwnership split: CD&R 51% / McKesson 49%
Read article
Trump offered US help to Russia after a Siberian plague lab death — the biodefense trade bid 20% before the contract reality set in insight cover
Markets / Event
NVAX · EBS•13 min read

Trump offered US help to Russia after a Siberian plague lab death — the biodefense trade bid 20% before the contract reality set in

On October 2, 2026, a 28-year-old lab worker at Russia's [Irkutsk] Anti-Plague Institute died of \"pneumonia of unknown origin,\" prompting the quarantine of roughly 200 contacts — all reportedly testing negative — and a denial from Rosporebnadzor that any pathogenic-material exposure occurred. He took four days to offer US help; Novavax shot 20%, Emergent BioSolutions gained 14% and a basket of outbreak names rallied, even though no federal contract was triggered, [BARDA]'s FY2026 budget request was just cut by $361 million, and the Strategic National Stockpile already carries stockpiled antibiotics labeled for plague. The biodefense trade has caught a headline, not a contract.

Event Date: 2026-10-06Topic Type: Markets / Event
Read article
Vaxcyte Catapults Past Pfizer and Merck With a 31-Valent Phase 3 Beat — The $6.5B PCV Franchise Is Now on Notice insight cover
Earnings
PCVX · PFE•12 min read

Vaxcyte Catapults Past Pfizer and Merck With a 31-Valent Phase 3 Beat — The $6.5B PCV Franchise Is Now on Notice

Vaxcyte's VAX-31 met non-inferiority on every serotype shared with Pfizer's Prevnar 20 and Merck's Capvaxive in OPUS-1, and showed superiority on three unique strains. Shares jumped more than 50% to roughly $85 in pre-market trading on Oct. 6, 2026, lifting Vaxcyte's market cap toward $13B and forcing both incumbents to defend an ~$8B franchise that was already shrinking. The next12 months — OPUS-2, OPUS-3, and BLA timing — will determine how quickly the disruption becomes commercial reality.

OPUS-1 endpoints hit (28 shared serotypes): 28 / 28Non-inferiority vs Prevnar 20: 20 / 20
Read article

2026-10-04

The 100% Pharma Tariff Has a Back Door — 26 Companies Already Walked Through insight cover
Policy Trade
BAYRY•16 min read

The 100% Pharma Tariff Has a Back Door — 26 Companies Already Walked Through

Bayer's Oct. 2 announcement of a $2.2B Ohio plant was the loudest response to Trump's April 2026 patented-drug tariff — but the quieter story is the 26-company Most-Favored-Nation bloc covering 89% of the branded market, which has suspended the duty through January 2029. The wall is real for everyone else, and the second-order winners are the Indian and Chinese API producers, the Big 3 U.S. distributors, and the PBMs sitting between manufacturers and patients.

McKesson TTM revenue: $411.0BCencora TTM revenue: $332.8B
Read article

2026-10-03

Pennsylvania's 977 measles cases test Merck's $2.4B MMR bundle at exactly the wrong time — and expose the hollowness of Moderna's mRNA optionality insight cover
Industry News
MRK · MRNA•16 min read

Pennsylvania's 977 measles cases test Merck's $2.4B MMR bundle at exactly the wrong time — and expose the hollowness of Moderna's mRNA optionality

Pennsylvania crossed 977 measles cases on Oct 2, 2026 — 5 deaths, 195 hospitalizations, 39 counties — while Merck's $2.4B ProQuad-plus-M-M-R-II franchise is the only US product that can blunt it. Trump's Aug 10 executive order to split MMR into three separate doses is dead in practice: Merck and GSK say monovalent shots would take up to a decade to license, and a federal court has already stayed the ACIP votes needed to authorize the change. The outbreak sends real volume to Merck, modest pull-through to Bio-Rad, Qiagen and Abbott, and a low-eight-figure cost line to UnitedHealth, Humana, CVS Health and Elevance Health — while Moderna has no measles candidate anywhere in its pipeline and its Phase 3 CMV shot just failed.

Pennsylvania confirmed cases (2026): 977PA hospitalizations: 195
Read article
$90 Hits Only Half of Medicare: Why the Slush Fund, Not the Trust Fund, Is the Real Story insight cover
Industry News
UNH · HUM•12 min read

$90 Hits Only Half of Medicare: Why the Slush Fund, Not the Trust Fund, Is the Real Story

President Trump's one-time $90 rebate to roughly 20.8 million Original Medicare Part B enrollees — paid from a dormant $2 billion Medicare Improvement Fund on Oct. 8 — is a $1.87 billion cash transfer, not the recurring $22 billion shock the early headlines implied. By excluding Medicare Advantage members, dual-eligibles, and IRMAA payers, the carve-out sharpens the competitive pressure on UnitedHealth Group, Humana, and CVS Health heading into the annual enrollment period, while signaling a precedent for tapping never-used mandatory accounts that matters more than the check itself.

Total payout: $1.87BEligible beneficiaries: 20.8M
Read article

2026-10-02

Bayer's First US Pharma Plant Sits Between a $5B Stroke Drug and a $7.25B Roundup Tab insight cover
Industry News
16 min read

Bayer's First US Pharma Plant Sits Between a $5B Stroke Drug and a $7.25B Roundup Tab

Bayer is putting $2.2B into a 200-acre New Albany, Ohio campus — its first US pharmaceutical manufacturing site ever — anchored on Nubeqa, Kerendia and the soon-to-launch asundexian. The announcement comes three days after a 100% Section 232 tariff on imported patented drugs hit Bayer's books and ~20 days before a Missouri judge decides whether to sign off on a $7.25B Roundup class settlement, making this the cleanest test yet of whether a German pharma giant tied up in US litigation can still fund a decade of US growth.

Headline capex: $2.2BOperational timeline: 2031 / 2034
Read article

2026-09-30

AstraZeneca just bought the bispecific Pfizer, Merck and Bristol can't out-license — for 12% of a one-drug biotech insight cover
Industry News
AZN · SMMT•14 min read

AstraZeneca just bought the bispecific Pfizer, Merck and Bristol can't out-license — for 12% of a one-drug biotech

On Sept 28, 2026, AstraZeneca wrote a $2.0B check for ~12% of Summit Therapeutics and a clinical collaboration pairing ivonescimab with its CLDN18.2 ADC sonesitatug vedotin. The bet was priced days after ivonescimab beat pembrolizumab on overall survival in HARMONi-2 and Sone-Ve hit its own Phase 3 endpoint in gastric cancer — and it gives [azn] combination rights competitors can't easily replicate, because the asset they want is locked inside a tiny company whose largest shareholder just pocketed $2B from a rival.

Equity investment: $2.0BImplied ownership: ~12.0% basic / ~10.6% fully dilu
Read article

What to expect

Evidence-first notes with a visible point of view.

This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.

Expect direct analysis, not generic commentary.

Expect the data to be explicit and the argument to be easy to follow.